Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 252

Similar articles for PubMed (Select 18510598)

1.

White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.

Stenset V, Hofoss D, Johnsen L, Skinningsrud A, Berstad AE, Negaard A, Reinvang I, Gjerstad L, Fladby T.

Acta Neurol Scand. 2008 Dec;118(6):373-8. doi: 10.1111/j.1600-0404.2008.01045.x. Epub 2008 May 28.

PMID:
18510598
2.

Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.

Stenset V, Johnsen L, Kocot D, Negaard A, Skinningsrud A, Gulbrandsen P, Wallin A, Fladby T.

Neurology. 2006 Sep 12;67(5):830-3.

PMID:
16966546
3.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
4.

White matter lesion subtypes and cognitive deficits in patients with memory impairment.

Stenset V, Hofoss D, Berstad AE, Negaard A, Gjerstad L, Fladby T.

Dement Geriatr Cogn Disord. 2008;26(5):424-31. doi: 10.1159/000165355. Epub 2008 Oct 23.

PMID:
18946220
5.

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

Herukka SK, Hallikainen M, Soininen H, Pirttilä T.

Neurology. 2005 Apr 12;64(7):1294-7.

PMID:
15824371
6.

CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL.

Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A.

Eur J Neurol. 2008 Nov;15(11):1252-5. doi: 10.1111/j.1468-1331.2008.02277.x. Epub 2008 Sep 18.

PMID:
18803653
7.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
8.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
9.

Markers of Alzheimer's disease in a population attending a memory clinic.

Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C.

Alzheimers Dement. 2009 Jul;5(4):307-17. doi: 10.1016/j.jalz.2009.04.1235.

PMID:
19560101
10.

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.

Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.

J Int Neuropsychol Soc. 2008 Jul;14(4):582-90. doi: 10.1017/S135561770808079X.

PMID:
18577287
11.

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

Sjögren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A.

J Neurosci Res. 2001 Nov 1;66(3):510-6.

PMID:
11746370
12.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19.

PMID:
17374949
13.

Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.

Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, Multhaup G, Wiltfang J, Schäfer S, Wirths O, Bayer TA.

J Neural Transm. 2008 Dec;115(12):1651-9. doi: 10.1007/s00702-008-0136-2. Epub 2008 Oct 30.

PMID:
18972062
14.

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.

Arch Neurol. 2000 Jan;57(1):100-5.

PMID:
10634455
15.

Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42.

Thorvaldsson V, Nordlund A, Reinvang I, Blennow K, Zetterberg H, Wallin A, Johansson B.

Int Psychogeriatr. 2010 Jun;22(4):598-606. doi: 10.1017/S1041610210000335. Epub 2010 Mar 26.

PMID:
20338079
16.

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E.

Dement Geriatr Cogn Disord. 2007;24(2):118-24. Epub 2007 Jul 2.

PMID:
17622715
17.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

18.

Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.

Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316.

PMID:
20142530
19.

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O.

Neurology. 2010 May 11;74(19):1531-7. doi: 10.1212/WNL.0b013e3181dd4dd8.

PMID:
20458070
20.

Longitudinal change of biomarkers in cognitive decline.

Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Oct;68(10):1257-66. doi: 10.1001/archneurol.2011.123. Epub 2011 Jun 13.

PMID:
21670386
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk